title: Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia.
abstract: The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18-79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS: P = 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (P = 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (P = 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML.
authors.affiliation: Clinic for Hematology, Clinical Center of Serbia, Koste Todorovica 2, 11000 Belgrade, Serbia. irenadju@eunet.rs
authors.forename: Irena
authors.initials: I
authors.lastname: Djunic
authors.forename: Marijana
authors.initials: M
authors.lastname: Virijevic
authors.forename: Vladislava
authors.initials: V
authors.lastname: Djurasinovic
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Novkovic
authors.forename: Natasa
authors.initials: N
authors.lastname: Colovic
authors.forename: Nada
authors.initials: N
authors.lastname: Kraguljac-Kurtovic
authors.forename: Ana
authors.initials: A
authors.lastname: Vidovic
authors.forename: Nada
authors.initials: N
authors.lastname: Suvajdzic-Vukovic
authors.forename: Dragica
authors.initials: D
authors.lastname: Tomin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D019002:CD56 Antigen / Q000096:biosynthesis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D019002:CD56 Antigen
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:420-8
references.pmid: 18024660
references.citation: Br J Haematol. 1976 Aug;33(4):451-8
references.pmid: 188440
references.citation: Cancer. 2007 Apr 1;109(7):1376-83
references.pmid: 17326052
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:56-61
references.pmid: 21239771
references.citation: Ann Hematol. 1992 Feb;64(2):78-82
references.pmid: 1372833
references.citation: Leuk Res. 2004 Jan;28(1):43-8
references.pmid: 14630079
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:1-11
references.pmid: 19074046
references.citation: Br J Haematol. 2007 Feb;136(4):624-7
references.pmid: 17223919
references.citation: Am J Clin Pathol. 1995 Aug;104(2):212-5
references.pmid: 7639197
references.citation: Haematologica. 2002 Mar;87(3):250-6
references.pmid: 11869936
references.citation: Blood. 1997 Aug 15;90(4):1643-8
references.pmid: 9269784
references.citation: Leukemia. 2001 Aug;15(8):1161-4
references.pmid: 11480556
references.citation: Haematologica. 2002 Nov;87(11):1135-40
references.pmid: 12414342
references.citation: Hematol Oncol. 2009 Sep;27(3):148-53
references.pmid: 19274612
references.citation: Blood. 2010 Jan 21;115(3):453-74
references.pmid: 19880497
references.citation: Leuk Res. 2011 Apr;35(4):492-8
references.pmid: 20684989
references.citation: Cancer. 2006 Mar 1;106(5):1090-8
references.pmid: 16435386
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Oncologist. 2009 Mar;14(3):222-32
references.pmid: 19282349